Replies to post #41793 on Biotech Values

[DewDiligence]

> MNTA – That's wonderful news! …My heartiest congrats to all the Momenta holders! Hi Dew, Your story stock is becoming real:-) <

Yes, this is great news for MNTA. But MNTA is still a story stock until the FDA approves MNTA’s generic Lovenox and rejects (or takes no action on) the generic-Lovenox applications from TEVA and Amphistar. Only then will investors have undisputable proof that MNTA’s technology can form the basis of a lucrative business.

In the meantime, enjoy the ride. Regards, Dew

[DewDiligence]

> MNTA – What a relief to hear since I didn't have any protection.<

MNTA is now down 17%. Maybe you would have done better with protection after all :-)

Although today’s drop is a little surprising, the rationale for it is presumably the sentiment I expressed earlier today that MNTA remains a “story stock” until the FDA validates its technology with an approval of the Lovenox ANDA as well as a rejection of the ANDA from TEVA/Amphastar.

Praveen, you tend to get easily impressed with promises of greatness, IMO. Perhaps you ought to be a little more skeptical in your approach to biotech investing. Regards, Dew